疑似早产型子痫前期中的胎盘生长因子:证据综述与实施可行性
该综述总结了胎盘生长因子(PlGF)及其与可溶性fms样酪氨酸激酶1(sFlt-1)作为早产型子痫前期生物标志物的证据,指出基于PlGF的检测可加速诊断并通过风险分层减少孕产妇不良结局。综述还描述了在临床实践中实施PlGF检测的可行性与挑战,目前该检测已在多个国家逐步开展。
要点
- PlGF与sFlt-1是早产型子痫前期的有价值生物标志物,可加速诊断。
- 基于PlGF的检测通过风险分层减少孕产妇不良结局,对高风险孕妇加强监测。
- 基于PlGF的检测已在多个国家逐步进入临床实践。
核心结论
- 血管生成生物标志物包括PlGF和sFlt-1是早产型子痫前期的有价值生物标志物,可加速诊断并通过风险分层减少孕产妇不良结局。
研究设计与样本
- 综述,检索范围原文未报告。
主要发现
- 基于PlGF的检测可加速诊断并通过风险分层减少孕产妇不良结局,对高风险孕妇加强监测。
- 基于PlGF的检测已在多个国家逐步进入临床实践。
临床怎么用
- 综述旨在帮助医疗服务提供者理解基于PlGF检测的证据,并描述实施的可行性与挑战。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite extensive research, the pathophysiology and prevention of pre-eclampsia remain elusive, diagnosis is challenging, and pre-eclampsia remains associated with adverse maternal and perinatal outcomes. Angiogenic biomarkers, including placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), have been identified as valuable biomarkers for preterm pre-eclampsia, accelerating diagnosis and reducing maternal adverse outcomes by risk stratification, with enhanced surveillance for high-risk women. PlGF-based testing is increasingly being implemented in clinical practice in several countries. This review provides healthcare providers with an understanding of the evidence for PlGF-based testing and describes the practicalities and challenges to implementation. TWEETABLE ABSTRACT: Placental growth factor in pre-eclampsia: evidence and implementation of testing.
引用
- Hurrell A, Beardmore-Gray A, Duhig K, et al. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation. BJOG. 2020. PMID: 32701207. doi:10.1111/1471-0528.16425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。